+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of imbalanced interhemispheric functional coordination in early therapeutic efficacy in major depressive disorder

Prognostic value of imbalanced interhemispheric functional coordination in early therapeutic efficacy in major depressive disorder

Psychiatry Research. Neuroimaging 255: 1-8

This study aims to explore the early response of antidepressant therapy by measuring the voxel-mirrored homotopic connectivity (VMHC) in major depressive disorder (MDD). Eighty-two MDD patients [n=42 treatment-responsive depression (RD) and n=40 non-responding depression (NRD)] and n=50 normal controls (NC) underwent clinical measures and a magnetic resonance imaging scan, and the VMHC values were calculated. Receiver operating characteristic (ROC) curve analysis was applied to determine the capability of altered VMHC to distinguish NRD. The NRD showed significantly decreased VMHC in bilateral precuneus (PCU) and inferior temporal gyrus (ITG), and increased VMHC in middle frontal gyrus (MFG) and caudate nucleus as compared to RD. When compared with NC, the NRD exhibited reduced VMHC in bilateral cerebellum anterior lobe, thalamus and postcentral gyrus. Moreover, VHMC in medial frontal gyrus, postcentral gyrus and precentral gyrus were significantly decreased in RD. Correlation analysis showed that reduced VMHC in PCU was negatively correlated with the baseline HAMD score of the NRD group. The ROC curve indicated that the combined changes of the three regional VMHC (PCU, ITG and MFG) could effectively identify NRD. The current study suggests that interhemispheric asynchrony may represents a novel neural trait underlying the prediction of early therapeutic outcome in MDD.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637799

Download citation: RISBibTeXText

PMID: 27497214

DOI: 10.1016/j.pscychresns.2016.07.011

Related references

Decreased interhemispheric resting-state functional connectivity in first-episode, drug-naive major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 41: 24-29, 2013

Interhemispheric functional connectivity and its relationships with clinical characteristics in major depressive disorder: a resting state fMRI study. Plos One 8(3): E60191, 2013

Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. European Neuropsychopharmacology 26(2): 378-389, 2016

Evaluation of therapeutic efficacy and pharmacokinetics of controlled release of trazodone in patients with major depressive disorder. Minerva Psichiatrica 35(4): 231-235, 1994

Serotonin transporter clustering in blood lymphocytes as a putative biomarker of therapeutic efficacy in major depressive disorder. Journal of Affective Disorders 137(1-3): 46-55, 2012

Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy. Journal of Gastroenterology and Hepatology 30(6): 1009-1014, 2016

Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment. Primary Care Companion for Cns Disorders 18(5), 2017

Impaired interhemispheric connectivity in medication-naive patients with major depressive disorder. Journal of Psychiatry and Neuroscience 38(1): 43-48, 2013

Effects of age on paroxetine efficacy in patients with major depressive disorder who do not exhibit an early response to treatment. Clinical Neuropharmacology 38(1): 6-10, 2015

Zhiqiaochuanxiong decoction for major depressive disorder complicated by functional dyspepsia: a case report with fast-acting efficacy. Journal of Traditional Chinese Medicine 35(6): 697-702, 2016

Sub-hubs of baseline functional brain networks are related to early improvement following two-week pharmacological therapy for major depressive disorder. Human Brain Mapping 36(8): 2915-2927, 2016

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. International Clinical Psychopharmacology 29(4): 197-205, 2015

Subcortical volumes differentiate Major Depressive Disorder, Bipolar Disorder, and remitted Major Depressive Disorder. Journal of Psychiatric Research 68: 91-98, 2016

Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Psychiatry Research 176(1): 85-87, 2010

Major depressive disorder in chronic heart failure patients: Does silent cerebral infarction cause major depressive disorder in this patient population?. Turk Kardiyoloji Dernegi Arsivi 43(6): 505-512, 2015